Nurix Therapeutics, Inc.

1700 Owens Street, Suite 205

San Francisco, CA 94158

July 21, 2020


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



Suzanne Hayes

Alan Campbell

Tracey McKoy

Terence O’Brien

Re:   Nurix Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-239651) originally filed July 2, 2020, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-39398) filed July 20, 2020

Requested Date: July 23, 2020

Requested Time: 4:00 PM Eastern Time

Ladies and Gentlemen:

Nurix Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Michael A. Brown or Amanda L. Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Brown at (415) 875-2432 or, in his absence, Ms. Rose at (206) 389-4553.

* * *


/s/ Hans van Houte

  Hans van Houte
  Chief Financial Officer



Arthur T. Sands, President and Chief Executive Officer

Christine Ring, General Counsel

Nurix Therapeutics, Inc.

Michael A. Brown, Esq.

Robert A. Freedman, Esq.

Amanda L. Rose, Esq.

Fenwick & West LLP


[Signature Page to Company Acceleration Request Letter]